A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has ... by introducing a gene known as BCL11A which down-regulates the production of the adult form of the oxygen-carrying ...

CRISPR Therapeutics is developing CTX112 for both ... cells are edited at the erythroid specific enhancer region of the BCL11A gene. This edit results in the production of high levels of fetal ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

CRISPR Therapeutics is developing CTX112 for both hematologic malignancies ... s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene.

ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...